Detecting overall survival benefit derived from survival postprogression rather than progression-free survival.

Item

http://www.wikidata.org/entity/Q36173497

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Detecting overall survival ben ...... han progression-free survival.

@ast

Detecting overall survival ben ...... han progression-free survival.

@en

type

Item

label

Detecting overall survival ben ...... han progression-free survival.

@ast

Detecting overall survival ben ...... han progression-free survival.

@en

prefLabel

Detecting overall survival ben ...... han progression-free survival.

@ast

Detecting overall survival ben ...... han progression-free survival.

@en

P1476

Detecting overall survival ben ...... han progression-free survival.

@en

P2093

Guosheng Yin

http://www.w3.org/2001/XMLSchema#string

Kentaro Sakamaki

http://www.w3.org/2001/XMLSchema#string

Satoshi Morita

http://www.w3.org/2001/XMLSchema#string

P2860

Detecting an overall survival benefit that is derived from progression-free survival

Efficacy of eribulin in women with metastatic breast cancer: a pooled analysis of two phase 3 studies.

FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial.

Overall survival as the outcome for randomized clinical trials with effective subsequent therapies

Randomized phase II trial designs with biomarkers.

Progression-free survival as a surrogate endpoint of overall survival in patients with metastatic renal cell carcinoma.

Overall survival and post-progression survival in advanced breast cancer: a review of recent randomized clinical trials.

Should progression-free survival be the primary measure of efficacy for advanced NSCLC therapy?

Alternative end points to evaluate a therapeutic strategy in advanced colorectal cancer: evaluation of progression-free survival, duration of disease control, and time to failure of strategy--an Aide et Recherche en Cancerologie Digestive Group Stud

Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancer.

P31

scholarly article

P356

10.1093/JNCI/DJV133

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

107

http://www.w3.org/2001/XMLSchema#string

P577

2015-05-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25956357

http://www.w3.org/2001/XMLSchema#string

P932

4609552

http://www.w3.org/2001/XMLSchema#string